Qiming Venture Partners Named to Tech Pioneer T50 — China's Top 50 Vanguard Tech Investment Institutions
The ranking aims to strengthen industry consensus around the commercialization of early-stage technology, guiding investment institutions to more precisely align with the strategies of "investing early and small," nurturing innovation across the full sci-tech lifecycle, and channeling capital toward strategic emerging industries.
At the recently held 2025 (25th) China Venture Capital Forum, the Tech T50 — China's Top 50 Pioneer Tech Investment Institutions list was officially released. The list aims to strengthen industry consensus around early-stage tech commercialization, guide investment institutions to more precisely align with the strategy of "investing early and small," cultivate full sci-tech innovation cycles, and direct resources toward strategic emerging industries.
Qiming Venture Partners was selected for the Tech T50 — China's Top 50 Pioneer Tech Investment Institutions.
Qiming Venture Partners
Selected for
Tech T50 — China's Top 50 Pioneer Tech Investment Institutions
· Tech T50 — China's Top 50 Pioneer Tech Investment Institutions
The list was jointly released by Shanghai Science and Technology Innovation Finance Research Institute, Shanghai Angel Club, and Pujiang Science and Technology Review, with data support from Most Innovation Community and Ruisi Analysis. Focusing on major annual topics in the sci-tech innovation field, and guided by the principle of "empowering sci-tech innovation at the source and promoting technology transfer," the organizers conducted a comprehensive evaluation of candidate institutions based on core dimensions including contribution to technology commercialization and investment performance. Through data analysis, questionnaire surveys, and expert review, the list ultimately selected 50 institutions as the "pioneer forces" with outstanding comprehensive performance in China's tech investment sector.
In its selection report, the Shanghai Science and Technology Innovation Finance Research Institute stated that China's tech investment sector is undergoing systemic and structural transformation. Investment direction is accelerating toward deeper penetration of strategic emerging industries, investment entities are becoming increasingly diversified, and investor patience has notably strengthened. This series of shifts is injecting more sustainable and resilient momentum into technological innovation.
Source | Shanghai Science and Technology Innovation Finance Research Institute
Past Highlights
Qiming Honors | Qiming Venture Partners Selected for China Fund's Second Annual Private Equity and Venture Capital Yinghua Demonstration Cases Qiming Honors | Qiming Venture Partners and Investors Selected for 36Kr's 2025 China Industrial Investor Annual List Qiming Honors | Qiming Venture Partners and 6 Portfolio Companies Selected for 2025 Investment Institution Soft Power Rankings
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, the firm has focused on investing in outstanding early and growth-stage companies in Technology and Healthcare.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies, of which more than 210 have listed on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 companies have become recognized unicorns or super-unicorns in their industries.
Many companies in Qiming Venture Partners' portfolio have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Unisound (09678.HK), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), SinoCellTech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, Biren Technology, and others.